Clinical trials: SLE, open to volunteers
Systemic Lupus Erthematosus (SLE)
Team-based Implementation of Hypertension Management in Childhood Lupus
The goal of this study is to compare the effectiveness of widely used implementation strategies to promote adherence to guideline-concordant evidence-based practices for monitoring and controlling blood pressure in patients with…
- Trial name
- ABOUT TIME (NCT07792733)
- Testing
- Health Navigator Engagement, Team Charter with Performance Monitoring, Pre-visit worksheet
- Volunteers
- 1,200 people
- Sponsor
- Boston Children's Hospital
Systemic Lupus Erthematosus (SLE)
2-HOBA in Systemic Lupus Erythematosus
This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE.
- Trial name
- NCT07225543
- Testing
- 2-HOBA acetate (2-Hydroxybenzlamine acetate)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt University Medical Center
Systemic Lupus Erythematosus (SLE)
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
This study is a single-arm, open-label clinical study designed to evaluate the safety and tolerability of QT-019B in subjects with refractory SLE and to determine the RD.
- Trial name
- NCT07444307
- Testing
- QT-019B Cell Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hangzhou Qihan Biotech Co., Ltd.
SLE - Systemic Lupus Erythematosus
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial featuring single and multiple ascending doses.
- Trial name
- NCT07177911
- Testing
- CC312
- Where
- China
- Volunteers
- 32 people
- Sponsor
- CytoCares Inc
Systemic Lupus Erythematosus
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KP104 in participants with systemic lupus erythematosus (SLE)-Thrombotic microangiopathy (TMA).
- Trial name
- NCT05504187
- Testing
- KP104
- Volunteers
- 24 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
Gout, Rheumatoid Arthritis
Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments
Inflammatory rheumatic diseases affect 1% of the population. Treatment of such diseases should be based on disease activity, safety issues and other patient characteristics such as comorbidities (EULAR, 2022), leading to a higher…
- Conditions
- Gout, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus
- Trial name
- CAPTAIN (NCT05927688)
- Testing
- Therapeutic management following access by the physician to his patient's ePROs
- Where
- France
- Volunteers
- 352 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS)
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular…
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- in vivo CAR-T (NCT07413341)
- Testing
- TI-0032-III injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Systemic Lupus Erythematosus
Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
Lupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with…
- Trial name
- APLCLLDAS (NCT03138941)
- Where
- 20 sites in Australia, China and 9 more
- Volunteers
- 5,000 people
- Sponsor
- Monash University
Autoimmune Diseases, Autoinflammatory Diseases
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.
- Trial name
- NCT06417502
- Where
- 9 sites in China
- Volunteers
- 20,000 people
- Sponsor
- Peking Union Medical College Hospital
SLE - Systemic Lupus Erythematosus
CD19/BCMA CAR-T for SLE
The purpose of this clinical trial is to learn if CD19/BCMA CAR-T works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the CD19/BCMA CAR-T cell product.
- Trial name
- NCT07266337
- Testing
- CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chengdu Ucello Biotechnology Co., Ltd.
Systemic Lupus Erythematosus (SLE)
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Systemic Lupus Erythematosus
- Trial name
- NCT07215663
- Testing
- Cizutamig
- Where
- 17 sites in China
- Volunteers
- 47 people
- Sponsor
- Candid Therapeutics
SLE, LN
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN…
- Conditions
- SLE, LN, ANCA Associated Vasculitis, ANCA-Associated Glomerulonephritis
- Trial name
- NCT07203404
- Testing
- RD06-05 CART Cell Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Systemic Lupus Erythematosus
Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms.
- Trial name
- SHIELD (NCT05799378)
- Testing
- Hydroxychloroquine
- Where
- 12 sites in United States
- Volunteers
- 330 people
- Sponsor
- NYU Langone Health
Systemic Lupus Erythematosus (SLE)
It is an Observational Study That Compare Prognosis of Typical and Atypical Systemic Lupus Erythematosus Presentation
Atypical presentations of SLE including unusual initial symptoms, predominant organ involvement, late-onset disease and ANA-negative remain poorly characterized.
- Trial name
- NCT07350772
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Sohag University
Autoimmune Diseases
Deciphering the Genetic Architecture of Autoimmune Diseases
Background: Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause these diseases have been well studied in people with European and Asian ancestors.
- Trial name
- NCT06948110
- Where
- 2 sites in United States, Peru
- Volunteers
- 300 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
SLE (Systemic Lupus)
National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
SLE disease in Saudi Arabia is yet not well defined especially in a population with high consanguinity and high inbreeding coefficient . Up until now, there has been no prospective cohort study for SLE patients in Saudi Arabia.
- Trial name
- NCT04604990
- Where
- Saudi Arabia
- Volunteers
- 1,000 people
- Sponsor
- King Saud University
Lupus Erythematosus, Systemic
Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by heterogeneous clinical manifestations ranging from mild cutaneous involvement to severe multi-organ damage.
- Trial name
- NCT06881290
- Testing
- Vunakizumab (IL-17A inhibitor)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
This is an open-label, single-dose, prospective, monocenter, Phase I interventional study (not first-in-human) to assess the safety, tolerability, and preliminary efficacy of autologous anti-CD19 CAR-T cells as an advanced…
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis (SSc)
- Trial name
- CELL-ATTACK 1 (NCT07544225)
- Testing
- anti-CD19 CAR-T cells
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Lupus Nephritis
Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis
Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Among people living with SLE, 35-60% will develop LN during the course of the disease.
- Trial name
- REBIOLUP (NCT04449991)
- Testing
- Repeat kidney biopsy
- Where
- Sweden
- Volunteers
- 206 people
- Sponsor
- Karolinska Institutet